These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25946469)

  • 1. Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.
    Hui EP; Ma BB; Chan KC; Chan CM; Wong CS; To KF; Chan AW; Tung SY; Ng WT; Cheng AC; Lee VH; Chan SL; Loong HH; Kam MK; Leung SF; Ho R; Mo F; Ngan RK; Chan AT
    Cancer; 2015 Aug; 121(16):2720-9. PubMed ID: 25946469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Polymorphisms in ERCC1 Gene and Their Association with Response to Radiotherapy in Moroccan Patients with Nasopharyngeal Carcinoma.
    Benzeid R; Gihbid A; Tawfiq N; Benchakroun N; Bendahhou K; Benider A; Guensi A; El Benna N; Filali Maltouf A; Attaleb M; Chaoui I; Khyatti M; El Mzibri M
    Asian Pac J Cancer Prev; 2023 Jan; 24(1):93-99. PubMed ID: 36708557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin.
    Hua L; Chen S; Wei M; Shen Y; Long J; Lin Z; Meng Y; Guo C; Huang H; Tu X; Yao M
    Cancer Biother Radiopharm; 2022 Feb; 37(1):2-10. PubMed ID: 33764811
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA.
    Wang WY; Lin TY; Twu CW; Tsou HH; Lin PJ; Liu YC; Huang JW; Hsieh HY; Lin JC
    Oncotarget; 2016 Jul; 7(27):42608-42616. PubMed ID: 27191654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels.
    Wang WY; Twu CW; Chen HH; Jiang RS; Wu CT; Liang KL; Shih YT; Chen CC; Lin PJ; Liu YC; Lin JC
    Cancer; 2013 Mar; 119(5):963-70. PubMed ID: 23065693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERCC1 Cys8092Ala and XRCC1 Arg399Gln polymorphisms predict progression-free survival after curative radiotherapy for nasopharyngeal carcinoma.
    Jin H; Xie X; Wang H; Hu J; Liu F; Liu Z; Zhou J; Zhang Y; Xi X; Hu B; Liao Y; Tang J
    PLoS One; 2014; 9(7):e101256. PubMed ID: 25025378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Epstein-Barr Viral Deoxyribonucleic Acid Predicts Worse Outcomes in Pediatric Nonmetastatic Nasopharyngeal Carcinoma Patients: An Observational Study of 89 Cases in an Endemic Area.
    Shen T; Tang LQ; Gu WG; Luo DH; Chen QY; Li PJ; Mai DM; Mai HQ; Mo HY
    Medicine (Baltimore); 2015 Dec; 94(50):e1945. PubMed ID: 26683909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
    Twu CW; Wang WY; Chen CC; Liang KL; Jiang RS; Wu CT; Shih YT; Lin PJ; Liu YC; Lin JC
    Int J Radiat Oncol Biol Phys; 2014 May; 89(1):21-9. PubMed ID: 24725686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.
    Chen C; Wang F; Wang Z; Li C; Luo H; Liang Y; An X; Shao J; Li Y
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):315-22. PubMed ID: 23712330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
    Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
    Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic Changes of Post-Radiotherapy Plasma Epstein-Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer.
    Hui EP; Ma BBY; Lam WKJ; Chan KCA; Mo F; Ai QH; King AD; Wong CH; Wong KCW; Lam DCM; Tong M; Poon DMC; Li L; Lau TKH; Wong KH; Lo YMD; Chan ATC
    Clin Cancer Res; 2021 May; 27(10):2827-2836. PubMed ID: 33692028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.
    Hui EP; Li WF; Ma BB; Lam WKJ; Chan KCA; Mo F; Ai QYH; King AD; Wong CH; Guo R; Poon DMC; Tong M; Li L; Lau TKH; Wong KCW; Lam DCM; Lo YMD; Ma J; Chan ATC
    Ann Oncol; 2020 Jun; 31(6):769-779. PubMed ID: 32217076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.
    Takenaka T; Yano T; Kiyohara C; Miura N; Kouso H; Ohba T; Kometani T; Shoji F; Yoshino I; Maehara Y
    Lung Cancer; 2010 Jan; 67(1):101-7. PubMed ID: 19361884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERCC1 single nucleotide polymorphism C8092A, but not its expression is associated with survival of esophageal squamous cell carcinoma patients from Fujian province, China.
    Chen WH; Xin PL; Pan QX; Chen YY; Wang CR; Zhang ZS; Chen YF; Zhang CY; Cai WJ
    PLoS One; 2014; 9(9):e106600. PubMed ID: 25191856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma.
    Leung SF; Chan KC; Ma BB; Hui EP; Mo F; Chow KC; Leung L; Chu KW; Zee B; Lo YM; Chan AT
    Ann Oncol; 2014 Jun; 25(6):1204-8. PubMed ID: 24638904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients.
    Avinash Tejasvi ML; Maragathavalli G; Putcha UK; Ramakrishna M; Vijayaraghavan R; Anulekha Avinash CK
    Indian J Pathol Microbiol; 2020; 63(4):538-543. PubMed ID: 33154302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of ERCC1 polymorphisms and susceptibility to nasopharyngeal carcinoma.
    Yang ZH; Dai Q; Kong XL; Yang WL; Zhang L
    Mol Carcinog; 2009 Mar; 48(3):196-201. PubMed ID: 18615480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma.
    Ma B; Hui EP; King A; Leung SF; Kam MK; Mo F; Li L; Wang K; Loong H; Wong A; Chan CM; Chan KCA; Wong SCC; Lo YMD; Chan AT
    Br J Cancer; 2018 Apr; 118(8):1051-1055. PubMed ID: 29555989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma.
    Ma BB; King A; Lo YM; Yau YY; Zee B; Hui EP; Leung SF; Mo F; Kam MK; Ahuja A; Kwan WH; Chan AT
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):714-20. PubMed ID: 17011447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.